This randomized clinical trial determines whether nab-paclitaxel improves the outcomes of early and locally advanced ERBB2/HER2-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.
from Cancer via ola Kala on Inoreader http://ift.tt/2D5qgp1
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου